ANI Pharmaceuticals receives FDA approval for a new prefilled syringe format of Cortrophin Gel, available in 40 USP units/0.5 mL and 80 USP units/mL single-dose options.

Eton Pharmaceuticals' New Drug Application (NDA) for ET-400, an oral hydrocortisone solution, has been accepted by the FDA.

Madrigal Pharmaceuticals' Rezdiffra, the first FDA-approved treatment for MASH, is experiencing rapid sales growth, with over 6,800 patients on treatment in Q3 2024.

Tonix Pharmaceuticals announced positive Phase 3 topline results for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in fibromyalgia, meeting the pre-specified primary endpoint.

Phio Pharmaceuticals reports two patients with cutaneous squamous cell carcinoma achieved complete tumor clearance in a Phase 1b trial of PH-762.

The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity.

Acurx Pharmaceuticals reported promising trial results for ibezapolstat, a novel antibiotic targeting Gram-positive bacteria, including Clostridioides difficile.

Acurx Pharmaceuticals presented Phase 2 clinical trial results of ibezapolstat for *C. difficile* infection (CDI) at the Anaerobe Society of the Americas, highlighting its clinical efficacy.

Femasys Inc. has received FDA 510(k) clearance for FemChec, a diagnostic solution designed for checking the fallopian tubes using controlled contrast delivery.

Acelyrin's izokibep demonstrated statistically significant and clinically meaningful responses in a Phase 3 trial for moderate-to-severe hidradenitis suppurativa (HS).

Pomerantz Law Firm is investigating Sana Biotechnology for potential securities fraud related to the suspension of its SC291 and SC379 programs.

Incannex Healthcare reported positive Phase 2 results for PSX-001 in treating generalized anxiety disorder (GAD), showing significant anxiety reduction with synthetic psilocybin and psychotherapy.

Penumbra, Inc. has completed enrollment in its THUNDER clinical study, evaluating the Penumbra System with Thunderbolt Aspiration Tubing for acute ischemic stroke.

Intensity Therapeutics and SAKK collaborate on INVINCIBLE-4, a Phase 2 trial evaluating INT230-6 plus standard-of-care (SOC) versus SOC alone in localized triple-negative breast cancer (TNBC).

The FDA has granted Fast Track designation to Lipocine's LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.

CanSino Biologics has commenced a Phase II/III clinical trial for its Tdcp Adolescent and Adult vaccine, targeting individuals aged six years and older.

BioAge Labs is facing a class action lawsuit following the discontinuation of its Phase 2 STRIDES trial for azelaprag due to safety concerns.

AbbVie has filed a lawsuit against Genmab and ProfoundBio alleging misappropriation of trade secrets related to disaccharide technology in antibody-drug conjugates, which Genmab categorically refutes.

Genomadix and Mayo Clinic have entered a know-how license agreement to enhance telestroke services using precision medicine.